NCT02698189终止1 期
A Phase IB Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Hematologic Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 9
- 主要终点
- Percentage of Participants With a Dose Limiting Toxicity (DLT)
研究概览
简要总结
This is a study to determine the recommended dose of birabresib (MK-8628) for further studies in participants with acute myeloid leukemia (AML) including AML de novo and AML secondary to myelodysplastic syndrome (MDS) and in participants with diffuse large B cell lymphoma (DLBCL). The recommended dose will be established by evaluating dose limiting toxicity (DLT), safety, tolerability, and early efficacy signals.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of AML (AML de novo and post-MDS) or DLBCL
- •AML participants must have the following malignancy criteria: measurable and evaluable disease per tumor response criteria; ≥ 5% bone marrow blasts without alternate causality; and > 90 days since allogeneic stem cell transplantation relapse in participants relapsing after transplant
- •AML participants who are Philadelphia chromosome positive must have received ≥ 2 lines of therapy, including 2 bcr-abl tyrosine-kinase (TK) inhibitors (among imatinib, nilotinib and dasatinib), or only 1 line including 1 TK inhibitor if the relapse/refractoriness is associated with the detection of a resistance mutation to these inhibitors
- •AML participants < 60 years old must be in second or further relapse or relapsing after allogeneic stem cell transplantation regardless of number of relapses
- •AML participants ≥ 60 years old in first relapse with a disease-free interval < 12 months, or further relapse. First relapse is also applicable to AML post-MDS patients who have received prior treatment for MDS, but have not received prior treatment for AML.
- •DLBCL participants must have the following malignancy criteria: measurable and evaluable disease per tumor response criteria and ≥ 1 tumor mass that is ≥ 15 mm (long axis of lymph node) or ≥ 10 mm (short axis of lymph node or extranodal lesions) on spiral CT scan; failed 2 standard lines of therapy (at least one containing an anti-CD20 monoclonal antibody), or for whom such treatment is contraindicated.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1
- •An interval of ≥3 weeks since chemotherapy (≥ 6 weeks for nitrosoureas or mitomycin C), immunotherapy, hormone therapy or any other anticancer therapy or surgical intervention resection, or ≥3 half-lives for monoclonal antibodies, or ≥ 5 half-lives for other non-cytotoxic agents (whichever is longer)
- •Female participants must not be pregnant (negative urine or serum human chorionic gonadotropin test within 72 hours of study start)
- •Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of trial treatment through 90 days after the last dose of study medication
排除标准
- •Known primary central nervous system (CNS) malignancy or symptomatic or untreated CNS metastases
- •History of prior or concomitant malignancies within 3 years of study start
- •Has other serious illness or medical condition, such as active infection, unresolved bowel obstruction, psychiatric disorders, or cerebrovascular accident within 1 year of study start
- •Known history of human immunodeficiency virus (HIV) and/or active Hepatitis B or C infections
- •Has one of the following cardiac-related conditions: Congestive heart failure; angina pectoris; myocardial infarction (within 1 year of study start); uncontrolled hypertension; or uncontrolled arrhythmias
- •Is receiving other concomitant anticancer treatment
- •Has received high dose chemotherapy followed by autologous stem cell transplantation less than 90 days prior to first dose of study treatment
- •Is receiving concomitant therapy with strong CYP3A4 or CYP2A6 inhibitors or inducers
- •Is pregnant or breast-feeding
- •Participation in a clinical trial involving an investigational drug within 30 days of study start
- •Known additional malignancy that is progressing or requires active treatment
- •Has been previously treated with a Bromodomain and Extra-terminal (BET) inhibitor
- •Has acute promyelocytic leukemia, clinically uncontrolled disseminated intravascular coagulation, or peripheral cytopenia
- •Has chronic graft versus host disease (GVHD) or on immunosuppressive therapy for the control of GVHD
- •Has uncontrolled disease-related metabolic disorder
- •Unable to swallow oral medications, or has gastrointestinal condition deemed to jeopardize intestinal absorption.
研究组 & 干预措施
Birabresib 20 mg AML Cohort
Experimental
Participants in the AML cohort received 20 mg of birabresib as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
干预措施: Birabresib Dose 20 mg (Drug)
Birabresib 20 mg DLBCL Cohort
Experimental
Participants in the DLBCL cohort received 20 mg of birabresib as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
干预措施: Birabresib Dose 20 mg (Drug)
结局指标
主要结局
Percentage of Participants With a Dose Limiting Toxicity (DLT)
时间窗: From time of first dose up to the end of Cycle 1 (21-day cycle): up to 21 days
DLT was any of the following drug related (DR) investigator-assessed adverse events: pancytopenia with hypocellular bone marrow and no marrow blasts lasting for ≥6 weeks; Grade (G)4 hematologic toxicity lasting ≥7 days except thrombocytopenia; G4 thrombocytopenia; G3 thrombocytopenia with bleeding; G3 or 4 febrile or infection-related neutropenia; G4 nonhematologic (NH) toxicity (not laboratory); G3 NH toxicity (not laboratory), nausea, vomiting, or diarrhea lasting \>3 days despite supportive care; G3 or 4 NH laboratory abnormality requiring medical intervention, hospitalization, or persisting \>1 week; increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin, or international normalization ratio indicative of significant liver impairment; DR adverse event leading to discontinuation or ≥20% missed planned doses in Cycle 1; DR toxicity causing \>2 week delay in starting Cycle 2; or G5 toxicity.
次要结局
- Percentage of Participants Who Discontinued Study Treatment Due to an AE(From time of first dose until the end of treatment (up to 7 months))
- Percentage of Participants Who Experienced At Least One Adverse Event (AE)(From time of first dose until the end of follow-up (up to 8 months))
- Objective Response Rate (ORR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014)(Every 12 weeks starting from Cycle 5 (21-day cycle) until disease progression (up to 7 months))
- Area Under the Concentration-Time Curve of MK-8628 From Time 0 to Infinity (AUC 0-∞)(Up to 22 days post MK-8628 dose)
- Duration of Response (DOR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010)(Every 3 weeks starting from Cycle 2 (21-day cycle) until disease progression (up to 7 months))
- Disease Control Rate (DCR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010)(Every 3 weeks starting from Cycle 2 (21-day cycle) until disease progression (up to 7 months))
- Disease Control Rate (DCR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014)(Every 12 weeks starting from Cycle 5 (21-day cycle) until disease progression (up to 7 months))
- Observed Maximum Concentration (Cmax) of MK-8628(Up to 22 days post MK-8628 dose)
- Objective Response Rate (ORR) in the Acute Myeloid Leukemia (AML) Cohort Per International Working Group Criteria: European LeukemiaNet (Döhner et al, Blood, 2010)(Every 3 weeks starting from Cycle 2 (21-day cycle) until disease progression (up to 7 months))
- Duration of Response (DOR) in the Diffuse Large B Cell Lymphoma (DLBCL) Cohort Per International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014)(Every 12 weeks starting from Cycle 5 (21-day cycle) until disease progression (up to 7 months))
- Observed Minimum Concentration (Cmin) of MK-8628(Up to 22 days post MK-8628 dose)
- Apparent Terminal Half-life (t1/2) for MK-8628(Up to 22 days post MK-8628 dose)
- Apparent Total Body Clearance (CL/F) of MK-8628(Up to 22 days post MK-8628 dose)
- Apparent Volume of Distribution During the Terminal Phase (Vz/F) of MK-8628(Up to 22 days post MK-8628 dose)
- Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at 3 Hours Postdose on Day 1 of Cycle 1 (21-day Cycle)(Baseline (predose on Day 1 of Cycle 1 [21-day cycle]) and 3 hours postdose on Day 1 of Cycle 1 (21-day cycle))
- Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at 8 Hours Postdose on Day 1 of Cycle 1 (21-day Cycle)(Baseline (predose on Day 1 of Cycle 1 [21-day cycle]) and 8 hours postdose on Day 1 of Cycle 1 (21-day cycle))
- Time to Maximum Concentration (Tmax) of MK-8628(Up to 22 days post MK-8628 dose)
- Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at 12 Hours Postdose on Day 1 of Cycle 1 (21-day Cycle)(Baseline (predose on Day 1 of Cycle 1 [21-day cycle]) and 12 hours postdose on Day 1 of Cycle 1 (21-day cycle))
- Change From Baseline in Bromodomain and Extra-Terminal Domain (BET) Protein Target Gene Expression at Predose on Day 8 of Cycle 1 (21-day Cycle)(Baseline (predose on Day 1 of Cycle 1) and predose on Day 8 of Cycle 1 (21-day cycle))
研究者
相似试验
终止
1 期
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)NUT Midline Carcinoma (NMC)Triple Negative Breast Cancer (TNBC)Non-small Cell Lung Cancer (NSCLC)Castration-resistant Prostate Cancer (CRPC)NCT02698176Merck Sharp & Dohme LLC13
已完成
1 期
A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)Diffuse Large B-cell LymphomaMultiple MyelomaAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaNCT01713582Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)141
已完成
1 期
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)NUT Midline CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS MutationCastrate-resistant Prostate CancerCRPCPancreatic Ductal AdenocarcinomaNCT02259114Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)47
已完成
1 期
Study of BMS-986158 in Subjects With Select Advanced CancersAdvanced TumorsNCT02419417Bristol-Myers Squibb83
进行中（未招募）
1 期
MK-8628 Solid Tumor TrialEUCTR2015-005488-18-FROncoethix GmbH, a wholly owned subsidiary of Merck Sharp & Dohme Corp.13